A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma
Parker Institute for Cancer Immunotherapy · University of Pennsylvania · +6 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
698
total citations
- FWCI
- 38.61
- Percentile
- 100%
- References
- 44
Citations per year
Authors
37- ACAlexander C. HuangCorresponding
Parker Institute for Cancer Immunotherapy, University of Pennsylvania
- RORobert Orlowski
Merck & Co., Inc., Rahway, NJ, USA (United States), University of Pennsylvania
- XXXiaowei Xu
University of Pennsylvania
- RMRosemarie Mick
Parker Institute for Cancer Immunotherapy, University of Pennsylvania
- SMSangeeth M. George
Bristol-Myers Squibb (United States), Translational Therapeutics (United States), University of Pennsylvania
Topics & keywords
Topics
Keywords
- Medicine
- Melanoma
- Blockade
- Neoadjuvant therapy
- Immune system
- Oncology
- Immune checkpoint
- Adjuvant
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.